17.08.2021 • News

IVL to Buy Brazilian Surfactants Maker Oxiteno

Indorama Ventures (IVL), a world leader in the PET market, is continuing its acquisition spree, in its latest move buying Brazil’s Oxiteno Indústria e Comércio, a subsidiary of Ultrapar Participações. In picking up the new asset, IVL said it will gain a unique portfolio in high-value surfactants and significantly expand its existing Integrated Oxides and Derivatives (IOD) business.

The purchase price is $1.3 billion, subject to adjustments at closing, with a deferred payment of $150 million in 2024. IVL said the acquisition, which is subject to regulatory approval, is expected to complete in Q1 2022 and be earnings accretive immediately. The Thai group said it stands to realize synergies of $100 million by 2025 through portfolio adjustments, asset optimization and operational excellence.

As an integrated surfactants producer with 11 manufacturing plants and customers on four continents, Oxiteno will give IVL “strong customer relationships” in Brazil, Uruguay and Mexico, but also substantial growth potential in attractive end markets, such as in the US, where  the company has a new plant in Pasadena, Texas.

The Brazilian company’s focus on lowering greenhouse gas emissions is another plus of the deal, Indorama said. Going forward, it will assume a “unique market position” in technologies catering to niche, IP-rich and value-added applications in home & personal care, agrochemicals, coatings and oil & gas markets.

Together with the “world-class assets” acquired from US chemical producer Huntsman in 2020, IVL said the acquisition of Oxiteno will lead its newest business segment to become a major high-margin growth driver alongside its traditional PET commodities business, thereby creating a stronger and more resilient hybrid platform.

Author: Dede Williams, Freelance Journalist

PET giant Indorama Ventures is buying Brazil’s Oxiteno, a subsidiary of...
PET giant Indorama Ventures is buying Brazil’s Oxiteno, a subsidiary of Ultrapar Participações, for $1.3 billion. With the new asset, IVL said it will gain a unique portfolio in high-value surfactants and significantly expand its Integrated Oxides and Derivatives business. (c) Cytonn Photography

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

On Demand | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.